Filing Flows › Kiniksa Pharmaceuticals International (KNSA) › Q3 2026 › vs Q2 2026
Kiniksa Pharmaceuticals International (KNSA) Q3 2026 vs Q2 2026 (quarter over quarter)
Kiniksa Pharmaceuticals International's revenue rose $42.4M (+17%) from $244M in Q2 2026 to $286M in Q3 2026. Operating margin 19.0% against 11.2% (+7.8 pts).
Kiniksa Pharmaceuticals International, Q3 2026: revenue $286M (+58% year over year), operating margin 19.0%, net earnings $47.3M, operating cash flow $47.5M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Operating margin | 19.0% | 11.2% | +7.8 pts |
| Net margin | 16.6% | 10.4% | +6.1 pts |
| Free cash flow margin | 16.6% | 19.1% | -2.5 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $286M | $244M | $42.4M | +17% |
| Other income, net | $4.8M | $4.0M | $870K | +22% |
| Operating profit | $54.2M | $27.2M | $27.0M | +99% |
| Costs & expenses | $232M | $216M | $15.3M | +7% |
| Pre-tax earnings | $59.1M | $31.1M | $27.9M | +90% |
| Cost of revenue | $27.8M | $23.6M | $4.2M | +18% |
| Research & development | $32.8M | $40.9M | −$8.1M | -20% |
| SG&A | $65.4M | $63.9M | $1.5M | +2% |
| Other operating costs | $106M | $88.1M | $17.8M | +20% |
| Net earnings | $47.3M | $25.4M | $21.9M | +86% |
| Income tax | $11.7M | $5.7M | $6.0M | +105% |
| Depreciation & amortization | $490K | $472K | $18K | +4% |
| Share-based compensation | $13.1M | $11.6M | $1.4M | +12% |
| Working capital & other | $13.4M | −$9.7M | $23.0M | — |
| Operating cash flow | $47.5M | $47.2M | $352K | +0.7% |
| Free cash flow (OCF − capex) | $47.4M | $46.5M | $835K | +2% |
| Capital expenditures | $180K | $663K | −$483K | -73% |
Questions
How much did Kiniksa Pharmaceuticals International's revenue grow quarter over quarter in Q3 2026?
Kiniksa Pharmaceuticals International's revenue rose $42.4M (+17%) from $244M in Q2 2026 to $286M in Q3 2026. Operating margin 19.0% against 11.2% (+7.8 pts).